DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Stevens-Johnson syndrome and toxic epidermal necrolysis

Essential points for quick revision.

!
Epidermal necrolysis emergency

Skin pain, dusky atypical targets, blistering, detachment and erosive mucositis after medicine exposure indicate potential SJS or TEN with rapidly evolving skin failure.

Action: Stop suspected non-essential medicines immediately, admit to an experienced high-dependency environment and involve dermatology, critical care, ophthalmology and affected-mucosal specialties.

Synopsis

Recognise painful mucocutaneous epidermal necrolysis early, stop culprit medicines, quantify detachment, and coordinate intensive supportive and specialist care.

  • Painful skin, fever and mucosal erosion often precede obvious detachment; do not wait for large blisters to suspect SJS or TEN.
  • SJS involves under ten percent detached or detachable body surface, overlap ten to thirty percent, and TEN more than thirty percent.
  • Stop likely culprit and non-essential medicines immediately, using a dated timeline because latency and drug half-life influence causality.

Key red flags

Eye pain, photophobia, oral or genital erosions, skin tenderness, rapidly spreading dusky macules, blisters, positive epidermal shearing, fever, hypotension or oliguria requires emergency admission.

Pain before detachment

Marked skin tenderness or burning out of proportion to visible change is an early warning for evolving epidermal necrosis.

Investigation priorities

01
Medicine chronology and culprit assessmentFirst step

Stop high-risk exposures and estimate causality from start dates, withdrawal and half-life.

Management branches

Suspected epidermal necrolysisStop drugs and transfer early

Skin pain, dusky targetoid lesions, mucosal erosions or detachment appears after a plausible medicine.

  1. Withdraw plausible culprit and non-essential medicines, document exact exposure dates and obtain emergency dermatology plus critical-care assessment.
  2. Biopsy a fresh representative edge when safe, measure detached and detachable surface and initiate physiological monitoring without awaiting pathology.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom